Hannelore Ehrenreich studied medicine and veterinary medicine in Hanover and Munich, Germany. In parallel to her clinical training in neurology and psychiatry (in Munich and Göttingen) she had several grant-funded research positions in the USA (with Dr. Anthony S. Fauci, NIAID, NIH, Bethesda, MD), England and the Philippines. She is professor of neurology and psychiatry, and adjunct professor of biology and psychology, with teaching responsibilities at the University of Göttingen. She is head of Clinical Neuroscience at the Max Planck Institute of Experimental Medicine, Göttingen. Her research area of interest is translational neuroscience with focus on: (1) Molecular-cellular basis of neuropsychiatric diseases, particularly mechanisms of disease and endogenous neuroprotection/neuroregeneration (erythropoietin/EPO variants); (2) Preclinical and clinical research on neuroprotection/neuroregeneration in acute (ischemia/hypoxia, neurotrauma) and chronic diseases (schizophrenia, autism, MS, alcoholism); (3) Phenotype-based genetic association studies (PGAS) as a tool to understand the genotype contribution to (disease) phenotypes.
Martin Begemann studied medicine at the University of Hamburg and upon graduation carried on with basic research in developmental and cell biology as well as signal transduction (Rockefeller University, Columbia University, New York City). In 1996, Martin Begemann began his training as a clinical neurologist (Mount Sinai Medical Center, New York City) with a special emphasis on neuro-oncology (MSKCC, New York City) and was board certified in neurology in 2001 (ABPN). Martin Begemann joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine, Göttingen, in 2004. He recruited and examined several hundred patients for the multicenter schizophrenia cross-sectional study, initiated by the Göttingen Research Association for Schizophrenia (GRAS) as well as patients with bipolar and other affective disorders for phenotype-based genetic association studies (PGAS). In 2012, Martin Begemann was awarded the Venia legendi for clinical neuroscience by the University of Göttingen. He was board certified in neurology (2006) and psychiatry & psychotherapy (2012). Martin Begemann has a special interest in translational neuroscience with particular focus on schizophrenia, affective disorders and autism.
Ekrem Dere studied psychology at the University of Düsseldorf and obtained his diploma in 1999. In 2003 he was awarded with a PhD degree from the Faculty of Mathematics and Natural Sciences of the University of Düsseldorf. In 2007 he obtained his habilitation and venia legeni for psychology at the same university. He received a Heisenberg stipend from the DFG in 2009 and was recruited as a full professor for Pathology of Cerebral Aging at the Université Pierre and Marie Curie (UPMC Paris 6). Ekrem Dere joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine in Göttingen in 2012. Ekrem Dere is a behavioral neuroscientist with a particular research focus on the neurobiology and neuropathology of episodic memory and the behavioral functions of gap junctions in the brain. Moreover, he is interested in developing novel test paradigms for higher cognitive functions in mice.
Christian Hammer studied biology at the University of Heidelberg, with a focus on genetics, and obtained his diploma in 2006. From 2006 to 2010, he performed his PhD thesis in the Department of Human Molecular Genetics at the Institute of Human Genetics in Heidelberg. There, he investigated common genetic variation in genes of the serotonergic system with respect to their role in neuropsychiatric and neurogastrointestinal disorders. In December 2010, he obtained his PhD degree (‘summa cum laude’) for his dissertation ‘The role of common serotonin type 3 receptor variants in the pathoetiology of neuropsychiatric disorders’. Having gained extensive experience in both statistical analysis of case-control and pharmacogenetic association studies as well as diverse laboratory techniques, he continued to work at the Institute of Human Genetics in Heidelberg as a postdoctoral researcher, before joining Clinical Neuroscience at the Max Planck Institute of Experimental Medicine (MPIEM) in Göttingen in August 2011. His research focuses on phenotype-based genetic association studies, a novel approach to better understanding the contribution of genetic variation to the (schizophrenic) phenotype. In this context he is particularly interested in the role of infections and autoimmunity.
Hana Janova studied molecular biology and immunology at the Charles University in Prague where she obtained her master diploma in 2010. She then moved to Göttingen, where she worked as a PhD student in the laboratory of Prof. Uwe-Karsten Hanisch, Neuropathology Department of the University Medical Center Göttingen (UMG). She investigated the role of the TLR4 co-receptor CD14 in microglia during infection and other damage to the brain. After her PhD defense in 2014, she joined the lab of Jony Kipnis, Department of Neuroscience at the University of Virginia, USA, where she continued with her research on microglia. Specifically, she was interested in the role of microglia but also of other immune cells during spinal cord injury. Recently, Dr. Janova joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine in Göttingen. She is mainly interested in understanding the role of microglia in neuropsychiatric disorders with mild synaptic dysfunction, such as schizophrenia and autism. In this context, she is also exploring how erythropoietin (EPO) – endogenous and exogenous - influences microglial functions.
Marina Mitjans studied biology at the University of Barcelona, Spain. She obtained her Bachelor’s degree in 2009 and her Master’s degree in Neuroscience in 2011. From 2011 to 2014, she performed her PhD thesis in the Animal Biology Department of the Biology Faculty at the University of Barcelona. Her PhD thesis focused on Psychiatric Pharmacogenetics, in which she investigated genetic variability contributing to differences in clinical response to psychotropic drug treatment. Her PhD dissertation was qualified with “summa cum laude” and obtained the European PhD Quality Mention. In February 2015 she joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine, Göttingen, as an expert in genetic epidemiology of neuropsychiatric disorders. Her main interest focuses on the understanding of the contribution of genetic variability to the complex phenotype of schizophrenia, autism and other severe mental disorders.
Christoph Ott studied biology at the Free University in Berlin and the Georg-August-University in Goettingen. He obtained his Bachelor’s degree in 2009 and his Master’s degree with the major subject neurobiology in 2011. For his master thesis he joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine where he investigated the effects of erythropoietin in a mouse model of acute demyelination. In his PhD, also at Clinical Neuroscience, he focused on the erythropoietin system. He worked on the effects of erythropoietin on precursor cells in the hippocampus and investigated the expression of the classical erythropoietin receptor in the brain. Additionally, he was involved in projects concerning human serum autoantibodies against brain antigens. In January 2016, he obtained his PhD degree with summa cum laude. In an ongoing affiliation as postdoctoral researcher at the MPIEM he continues his work on erythropoietin receptor function in the brain.
Daniela Winkler studied biology at the University of Kassel and obtained her diploma in 2010. For her PhD, she joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine in Göttingen in 2010. During her PhD, she focused on the behavioral characterization of genetic mouse models targeting genes relevant to cognitive functions and neuropsychiatric disorders (especially autism spectrum disorder) and the development of more sophisticated testing tools for higher cognitive functions and complex behavioral traits in mice. She defended her cumulative PhD thesis in October 2014. Since January 2015 she holds a post-doctoral position to continue her scientific carrier as behavioural neuroscientist.
Liane Wüstefeld studied biochemistry at the University of Halle and Jena. Focusing on molecular medicine, she investigated a mouse model for schizophrenia and obtained her diploma in 2007. From 2008 to 2009 she worked as a doctoral student in neuroanatomy at the Center of Anatomy, University of Göttingen. For her PhD, she joined Clinical Neuroscience at the Max Planck Institute of Experimental Medicine in Göttingen and studied the erythropoietin/erythropoietin receptor system in the brain. She defended her PhD in May 2013. Since June 2013 she took over the role of a postdoctoral researcher in Clinical Neuroscience with teaching and supervision responsibilities. Her main interests are the effects of erythropoietin on neural precursor cells and microglia motility as well as the role and nature of the brain erythropoietin receptor.
Project: EPO/hypoxia in the brain – role for cognition
Project: PGAS (phenotype-based genetic association studies) in the extended GRAS data collection
Umer Javed Butt
Project: EPO/hypoxia in the brain – role for cognition
Project: Role of erythropoietin and erythropoietin receptor in the central nervous system
Project: Novel animal models of neuropsychiatric diseases: focus on Ambra1
Projects: Neuronal differentiation of human inducible pluripotent stem cells (IPSC) to explore autistic and other mental disease-relevant phenotypes
Project: Role of serum autoantibodies directed against brain epitopes for modulating brain functions
Expertise: Lab management, immunohistochemistry, PCR, genotyping
Expertise: Animal studies (behavior), Western blot analysis, immunohistochemistry, cell culture
Expertise: Cell culture, immunohistochemistry, PCR, animal studies
Project: GRAS study - environmental risk accumulation - autism
Expertise: Languages (conversation and correspondence), organisation, management